Cargando…

The efficacy of human placenta-derived mesenchymal stem cells on radiation enteropathy along with proteomic biomarkers predicting a favorable response

BACKGROUND: Radiation enteropathy is a common complication in patients with abdominopelvic cancer, but no treatment has yet been established. Stem cell therapy may be a viable therapeutic option because intestinal stem cells are highly vulnerable to ionizing radiation (IR) and stem cell loss explain...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Young-Min, Park, Jong-Min, Choi, Yong Soo, Jin, Hee, Lee, Yun-Sil, Han, Na-Young, Lee, Hookeun, Hahm, Ki Baik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414323/
https://www.ncbi.nlm.nih.gov/pubmed/28464953
http://dx.doi.org/10.1186/s13287-017-0559-5
_version_ 1783233350962511872
author Han, Young-Min
Park, Jong-Min
Choi, Yong Soo
Jin, Hee
Lee, Yun-Sil
Han, Na-Young
Lee, Hookeun
Hahm, Ki Baik
author_facet Han, Young-Min
Park, Jong-Min
Choi, Yong Soo
Jin, Hee
Lee, Yun-Sil
Han, Na-Young
Lee, Hookeun
Hahm, Ki Baik
author_sort Han, Young-Min
collection PubMed
description BACKGROUND: Radiation enteropathy is a common complication in patients with abdominopelvic cancer, but no treatment has yet been established. Stem cell therapy may be a viable therapeutic option because intestinal stem cells are highly vulnerable to ionizing radiation (IR) and stem cell loss explains its intractability to general treatment. Here, we investigated either prophylactic or therapeutic efficacy of human placenta-derived mesenchymal stem cells (hPDSCs) against radiation enteropathy and could identify biomarkers predicting a favorable response to stem cell therapy. METHODS: We challenged a radiation-induced enteropathy model with hPDSCs. After sacrifice, we checked the gross anatomy of small intestine, histology gross, and analyzed that, accompanied with molecular changes implicated in this model. RESULTS: hPDSCs significantly improved the outcome of mice induced with either radiation enteropathy or lethal radiation syndrome (P < 0.01). hPDSCs exerted inhibitory actions on inflammatory cytokines, the re-establishment of epithelium homeostasis was completed with increasing endogenous restorative processes as assessed with increased levels of proliferative markers in the hPDSCs group, and a significant inhibition of IR-induced apoptosis. The preservation of cells expressing lysozyme, and Musashi-1 were significantly increased in the hPDSC treatment group. Both preventive and therapeutic efficacies of hPDSCs were noted against IR-induced enteropathy. Label-free quantification was used to identify biomarkers which predict favorable responses after hPDSC treatment, and finally glutathione S-transferase-mu type, interleukin-10, and peroxiredoxin-2 were validated as proteomic biomarkers predicting a favorable response to hPDSCs in radiation enteropathy. CONCLUSIONS: hPDSCs may be a useful prophylactic and therapeutic cell therapy for radiation enteropathy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13287-017-0559-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5414323
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54143232017-05-03 The efficacy of human placenta-derived mesenchymal stem cells on radiation enteropathy along with proteomic biomarkers predicting a favorable response Han, Young-Min Park, Jong-Min Choi, Yong Soo Jin, Hee Lee, Yun-Sil Han, Na-Young Lee, Hookeun Hahm, Ki Baik Stem Cell Res Ther Research BACKGROUND: Radiation enteropathy is a common complication in patients with abdominopelvic cancer, but no treatment has yet been established. Stem cell therapy may be a viable therapeutic option because intestinal stem cells are highly vulnerable to ionizing radiation (IR) and stem cell loss explains its intractability to general treatment. Here, we investigated either prophylactic or therapeutic efficacy of human placenta-derived mesenchymal stem cells (hPDSCs) against radiation enteropathy and could identify biomarkers predicting a favorable response to stem cell therapy. METHODS: We challenged a radiation-induced enteropathy model with hPDSCs. After sacrifice, we checked the gross anatomy of small intestine, histology gross, and analyzed that, accompanied with molecular changes implicated in this model. RESULTS: hPDSCs significantly improved the outcome of mice induced with either radiation enteropathy or lethal radiation syndrome (P < 0.01). hPDSCs exerted inhibitory actions on inflammatory cytokines, the re-establishment of epithelium homeostasis was completed with increasing endogenous restorative processes as assessed with increased levels of proliferative markers in the hPDSCs group, and a significant inhibition of IR-induced apoptosis. The preservation of cells expressing lysozyme, and Musashi-1 were significantly increased in the hPDSC treatment group. Both preventive and therapeutic efficacies of hPDSCs were noted against IR-induced enteropathy. Label-free quantification was used to identify biomarkers which predict favorable responses after hPDSC treatment, and finally glutathione S-transferase-mu type, interleukin-10, and peroxiredoxin-2 were validated as proteomic biomarkers predicting a favorable response to hPDSCs in radiation enteropathy. CONCLUSIONS: hPDSCs may be a useful prophylactic and therapeutic cell therapy for radiation enteropathy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13287-017-0559-5) contains supplementary material, which is available to authorized users. BioMed Central 2017-05-02 /pmc/articles/PMC5414323/ /pubmed/28464953 http://dx.doi.org/10.1186/s13287-017-0559-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Han, Young-Min
Park, Jong-Min
Choi, Yong Soo
Jin, Hee
Lee, Yun-Sil
Han, Na-Young
Lee, Hookeun
Hahm, Ki Baik
The efficacy of human placenta-derived mesenchymal stem cells on radiation enteropathy along with proteomic biomarkers predicting a favorable response
title The efficacy of human placenta-derived mesenchymal stem cells on radiation enteropathy along with proteomic biomarkers predicting a favorable response
title_full The efficacy of human placenta-derived mesenchymal stem cells on radiation enteropathy along with proteomic biomarkers predicting a favorable response
title_fullStr The efficacy of human placenta-derived mesenchymal stem cells on radiation enteropathy along with proteomic biomarkers predicting a favorable response
title_full_unstemmed The efficacy of human placenta-derived mesenchymal stem cells on radiation enteropathy along with proteomic biomarkers predicting a favorable response
title_short The efficacy of human placenta-derived mesenchymal stem cells on radiation enteropathy along with proteomic biomarkers predicting a favorable response
title_sort efficacy of human placenta-derived mesenchymal stem cells on radiation enteropathy along with proteomic biomarkers predicting a favorable response
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414323/
https://www.ncbi.nlm.nih.gov/pubmed/28464953
http://dx.doi.org/10.1186/s13287-017-0559-5
work_keys_str_mv AT hanyoungmin theefficacyofhumanplacentaderivedmesenchymalstemcellsonradiationenteropathyalongwithproteomicbiomarkerspredictingafavorableresponse
AT parkjongmin theefficacyofhumanplacentaderivedmesenchymalstemcellsonradiationenteropathyalongwithproteomicbiomarkerspredictingafavorableresponse
AT choiyongsoo theefficacyofhumanplacentaderivedmesenchymalstemcellsonradiationenteropathyalongwithproteomicbiomarkerspredictingafavorableresponse
AT jinhee theefficacyofhumanplacentaderivedmesenchymalstemcellsonradiationenteropathyalongwithproteomicbiomarkerspredictingafavorableresponse
AT leeyunsil theefficacyofhumanplacentaderivedmesenchymalstemcellsonradiationenteropathyalongwithproteomicbiomarkerspredictingafavorableresponse
AT hannayoung theefficacyofhumanplacentaderivedmesenchymalstemcellsonradiationenteropathyalongwithproteomicbiomarkerspredictingafavorableresponse
AT leehookeun theefficacyofhumanplacentaderivedmesenchymalstemcellsonradiationenteropathyalongwithproteomicbiomarkerspredictingafavorableresponse
AT hahmkibaik theefficacyofhumanplacentaderivedmesenchymalstemcellsonradiationenteropathyalongwithproteomicbiomarkerspredictingafavorableresponse
AT hanyoungmin efficacyofhumanplacentaderivedmesenchymalstemcellsonradiationenteropathyalongwithproteomicbiomarkerspredictingafavorableresponse
AT parkjongmin efficacyofhumanplacentaderivedmesenchymalstemcellsonradiationenteropathyalongwithproteomicbiomarkerspredictingafavorableresponse
AT choiyongsoo efficacyofhumanplacentaderivedmesenchymalstemcellsonradiationenteropathyalongwithproteomicbiomarkerspredictingafavorableresponse
AT jinhee efficacyofhumanplacentaderivedmesenchymalstemcellsonradiationenteropathyalongwithproteomicbiomarkerspredictingafavorableresponse
AT leeyunsil efficacyofhumanplacentaderivedmesenchymalstemcellsonradiationenteropathyalongwithproteomicbiomarkerspredictingafavorableresponse
AT hannayoung efficacyofhumanplacentaderivedmesenchymalstemcellsonradiationenteropathyalongwithproteomicbiomarkerspredictingafavorableresponse
AT leehookeun efficacyofhumanplacentaderivedmesenchymalstemcellsonradiationenteropathyalongwithproteomicbiomarkerspredictingafavorableresponse
AT hahmkibaik efficacyofhumanplacentaderivedmesenchymalstemcellsonradiationenteropathyalongwithproteomicbiomarkerspredictingafavorableresponse